Inflammatory Hypothesis of Atherogenesis: Will Colchicine Be Added to the Armamentarium in the Prevention of Coronary Artery Disease?

Overview

Journal Am Heart J Plus

Specialty Cardiology & Vascular Diseases

Date 2024 Mar 29

PMID 38551014

Authors

Bahadir Simsek

Bugra Han Egeli

Atakan Selte

Bibin Varghese

Roger S Blumenthal

Erin Chew

Affiliations

Soon will be listed here.

Abstract

Chronic inflammation promotes the development and progression of atherosclerosis. Despite aggressive risk reduction, patients with coronary artery disease have a significant residual risk of myocardial infarction and cardiovascular death related in part to ongoing inflammation within coronary vasculature. In this review, we summarize the clinical trials that provide evidence for the inflammatory hypothesis of atherogenesis. Additionally, we describe studies suggesting colchicine may be able to reduce residual inflammatory risk via the NLRP3 pathway. Given its tolerable side effect profile, safety, and low cost, colchicine holds promise as an anti-inflammatory agent in primary and secondary prevention of coronary disease.

References

Libby P, Ordovas J, Auger K, Robbins A, Birinyi L, Dinarello C . Endotoxin and tumor necrosis factor induce interleukin-1 gene expression in adult human vascular endothelial cells. Am J Pathol. 1986; 124(2):179-85. PMC: 1888305. View

Tardif J, Kouz S, Waters D, Bertrand O, Diaz R, Maggioni A . Efficacy and Safety of Low-Dose Colchicine after Myocardial Infarction. N Engl J Med. 2019; 381(26):2497-2505. DOI: 10.1056/NEJMoa1912388. View

Ridker P, Danielson E, Fonseca F, Genest J, Gotto Jr A, Kastelein J . Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008; 359(21):2195-207. DOI: 10.1056/NEJMoa0807646. View

Brouhard G, Rice L . Microtubule dynamics: an interplay of biochemistry and mechanics. Nat Rev Mol Cell Biol. 2018; 19(7):451-463. PMC: 6019280. DOI: 10.1038/s41580-018-0009-y. View

Slobodnick A, Shah B, Krasnokutsky S, Pillinger M . Update on colchicine, 2017. Rheumatology (Oxford). 2017; 57(suppl_1):i4-i11. PMC: 5850858. DOI: 10.1093/rheumatology/kex453. View

Nidorf S, Fiolet A, Mosterd A, Eikelboom J, Schut A, Opstal T . Colchicine in Patients with Chronic Coronary Disease. N Engl J Med. 2020; 383(19):1838-1847. DOI: 10.1056/NEJMoa2021372. View

Deftereos S, Giannopoulos G, Papoutsidakis N, Panagopoulou V, Kossyvakis C, Raisakis K . Colchicine and the heart: pushing the envelope. J Am Coll Cardiol. 2013; 62(20):1817-25. DOI: 10.1016/j.jacc.2013.08.726. View

Roubille C, Richer V, Starnino T, McCourt C, McFarlane A, Fleming P . The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and meta-analysis. Ann Rheum Dis. 2015; 74(3):480-9. PMC: 4345910. DOI: 10.1136/annrheumdis-2014-206624. View

Bouabdallaoui N, Tardif J, Waters D, Pinto F, Maggioni A, Diaz R . Time-to-treatment initiation of colchicine and cardiovascular outcomes after myocardial infarction in the Colchicine Cardiovascular Outcomes Trial (COLCOT). Eur Heart J. 2020; 41(42):4092-4099. PMC: 7700755. DOI: 10.1093/eurheartj/ehaa659. View

10.

Arnett D, Blumenthal R, Albert M, Buroker A, Goldberger Z, Hahn E . 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019; 140(11):e596-e646. PMC: 7734661. DOI: 10.1161/CIR.0000000000000678. View

11.

Tong D, Quinn S, Nasis A, Hiew C, Roberts-Thomson P, Adams H . Colchicine in Patients With Acute Coronary Syndrome: The Australian COPS Randomized Clinical Trial. Circulation. 2020; 142(20):1890-1900. DOI: 10.1161/CIRCULATIONAHA.120.050771. View

12.

Ridker P . How Common Is Residual Inflammatory Risk?. Circ Res. 2017; 120(4):617-619. DOI: 10.1161/CIRCRESAHA.116.310527. View

13.

Ridker P, Howard C, Walter V, Everett B, Libby P, Hensen J . Effects of interleukin-1β inhibition with canakinumab on hemoglobin A1c, lipids, C-reactive protein, interleukin-6, and fibrinogen: a phase IIb randomized, placebo-controlled trial. Circulation. 2012; 126(23):2739-48. DOI: 10.1161/CIRCULATIONAHA.112.122556. View

14.

Martinon F, Petrilli V, Mayor A, Tardivel A, Tschopp J . Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature. 2006; 440(7081):237-41. DOI: 10.1038/nature04516. View

15.

Samuel M, Waters D . Will Colchicine Soon Be Part of Primary and Secondary Cardiovascular Prevention?. Can J Cardiol. 2020; 36(11):1697-1699. DOI: 10.1016/j.cjca.2020.06.012. View

16.

Shah B, Toprover M, Crittenden D, Jeurling S, Pike V, Krasnokutsky S . Colchicine Use and Incident Coronary Artery Disease in Male Patients With Gout. Can J Cardiol. 2020; 36(11):1722-1728. PMC: 8464652. DOI: 10.1016/j.cjca.2020.05.026. View

17.

Forkosh E, Kenig A, Ilan Y . Introducing variability in targeting the microtubules: Review of current mechanisms and future directions in colchicine therapy. Pharmacol Res Perspect. 2020; 8(4):e00616. PMC: 7327382. DOI: 10.1002/prp2.616. View

18.

Deftereos S, Giannopoulos G, Angelidis C, Alexopoulos N, Filippatos G, Papoutsidakis N . Anti-Inflammatory Treatment With Colchicine in Acute Myocardial Infarction: A Pilot Study. Circulation. 2015; 132(15):1395-403. DOI: 10.1161/CIRCULATIONAHA.115.017611. View

19.

Mueller S, Itin P, Haeusermann P . Muckle-Wells syndrome effectively treated with canakinumab: is the recommended dosing schedule mandatory?. Dermatology. 2011; 223(2):113-8. DOI: 10.1159/000331580. View

20.

Roubille F, Tardif J . Colchicine for Secondary Cardiovascular Prevention in Coronary Disease. Circulation. 2020; 142(20):1901-1904. DOI: 10.1161/CIRCULATIONAHA.120.051240. View